Key Highlights
- Pharmaceutical giant Eli Lilly to acquire AtaiBeckley at $6.75 per share in an all-cash transaction valued at $2.8 billion
- ATAI shares climbed 34% during premarket hours Thursday following the acquisition announcement
- The offer represents a 40% premium over AtaiBeckley’s trailing 30-day volume-weighted average trading price
- AtaiBeckley investors could secure an extra $2.50 per share based on achieving specific development and regulatory targets
- The announcement triggered a broader rally across psychedelic pharmaceutical companies, including 15% gains for GH Research and 7% for Compass Pathways
Pharmaceutical powerhouse Eli Lilly has finalized an agreement to acquire psychedelic therapy developer AtaiBeckley in a transaction valued at $2.8 billion in upfront cash, propelling ATAI shares up 34% during Thursday’s premarket session.
Shares of AtaiBeckley reached $7.19 in premarket activity, marking a 34.2% surge. The stock had initially spiked over 50% following Bloomberg’s late Wednesday report revealing that Lilly was in advanced negotiations to acquire the company at a substantial premium.
Under the terms of the agreement, Lilly will pay $6.75 in cash for each AtaiBeckley share. Additionally, shareholders stand to collect up to $2.50 in additional per-share payments contingent upon achieving predetermined developmental and regulatory benchmarks.
The $6.75 offer price delivers a significant 40% premium compared to AtaiBeckley’s volume-weighted average share price calculated over the previous 30 trading days.
Prior to the deal’s announcement, ATAI stock had already posted impressive gains in 2025, climbing 31% year-to-date through Wednesday’s market close.
A substantial portion of those 2025 returns materialized in April, when shares skyrocketed 22% in a single trading session after President Trump issued an executive directive aimed at accelerating FDA evaluation processes for psychedelic medications targeting severe mental health conditions.
AtaiBeckley’s flagship candidate is BPL-003, an intranasal delivery system for 5-MeO-DMT currently under development as a potential treatment for depression that has proven resistant to conventional therapies.
Psychedelic Sector Experiences Broad-Based Rally
The acquisition announcement created positive momentum throughout the psychedelic pharmaceutical sector. GH Research shares advanced 15%, while Compass Pathways gained 7%. Definium Therapeutics rose 6%, and Enveric Biosciences added 3% during premarket trading.
BMO Capital Markets equity analyst Evan Seigerman observed that while the transaction could surpass $2 billion in total value, continuing negotiations with additional pharmaceutical companies might drive the ultimate acquisition price even higher.
RBC Capital Markets analyst Brian Abrahams suggested the psychedelic pharmaceutical sector appears positioned for continued strength and is progressively gaining mainstream acceptance.
Eli Lilly Expands Neuroscience Portfolio
This acquisition aligns with Lilly‘s strategic pattern of pursuing targeted acquisitions, especially within the neuroscience therapeutic area. The company’s most recent major transaction was its $7.8 billion purchase of sleep disorder specialist Centessa Pharmaceuticals.
Lilly shares showed minimal movement Thursday, edging up just 0.3% in premarket trading.
According to LSEG market data, AtaiBeckley’s market capitalization totaled $1.97 billion as of Wednesday’s closing bell.
When combining the upfront cash payment with potential milestone-based payments, the total transaction value could reach $9.25 per share for AtaiBeckley investors.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
